Multiple sclerosis: Prospects and promise

Annals of Neurology

Volumn 74, Issue 3, 2013, Pages 317-327

  Hauser, Stephen L ^a   Chan, Jonah R ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; HLA DRB1 ANTIGEN; INTERFERON; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ARTICLE; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; GALACTOSYLCERAMIDASE GENE; GENE; GENE INTERACTION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REMYELINIZATION; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED;

EID: 84885635833     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24009     Document Type: Article

References (81)

1. Koch-Henriksen N, Sorensen PS,. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-532.
2. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009; 66: 513-520.
3. Goodin DS, Ebers GC, Cutter G, et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. BMJ Open 2012; 2: pii:e001972.
4. Rommer PS, Stuve O,. Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects. Curr Treat Options Neurol 2013; 15: 241-258.
5. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247-256.
6. Greenberg BM, Balcer L, Calabresi PA, et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol 2013; 70: 248-251.
7. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304. (Pubitemid 29416266)
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108. (Pubitemid 43157395)
9. Atkins HL, Freedman MS,. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics 2013; 10: 68-76.
10. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
11. Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5: 205-220.
12. Stellmann JP, Neuhaus A, Herich L, et al. Placebo cohorts in phase-3 MS treatment trials-predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PloS One 2012; 7: e50347.
13. Hauser SL, Goodin DS,. Harrison's neurology in clinical medicine. 3rd ed. New York, NY: McGraw-Hill Education, 2013.
14. Havrdova E, Galetta S, Stefoski D, Comi G,. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74 (suppl 3): S3-S7.
15. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688. (Pubitemid 351240747)
16. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779-1787.
17. International Multiple Sclerosis Genetics Consortium, 2 WTCCC. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 10: 214-219.
18. International Multiple Sclerosis Genetics Consortium. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet 2013 May 22. doi:pii: S0002-9297(13)00180-8. 10.1016/j.ajhg.2013.04.019. [Epub ahead of print].
19. International Multiple Sclerosis Genetics Consortium. High-density mapping uncovers 48 novel multiple sclerosis susceptibility loci. Nat Genet (in press).
20. Baranzini SE, Srinivasan R, Khankhanian P, et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010; 133: 2603-2611.
21. Ascherio A, Munger KL,. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007; 61: 288-299. (Pubitemid 46676728)
22. Ascherio A, Munger KL,. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504-513. (Pubitemid 47068132)
23. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115: 1352-1360. (Pubitemid 40629055)
24. Jafari N, van Nierop GP, Verjans GM, et al. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol 2010; 49: 26-31.
25. Franciotta D, Di Stefano AL, Jarius S, et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol 2011; 230: 160-163.
26. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L,. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler 2011; 17: 788-793.
27. Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012; 488: 675-679.
28. Wu C, Yosef N, Thalhamer T, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013; 496: 513-517.
29. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013; 496: 518-522.
30. Ho PP, Kanter JL, Johnson AM, et al. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med 2012; 4: 137ra73.
31. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012; 367: 115-123.
32. Nylander A, Hafler DA,. Multiple sclerosis. J Clin Invest 2012; 122: 1180-1188.
33. Mayo L, Quintana FJ, Weiner HL,. The innate immune system in demyelinating disease. Immunol Rev 2012; 248: 170-187.
34. Davidson MG, Alonso MN, Yuan R, et al. Th17 cells induce Th1-polarizing monocyte-derived dendritic cells. J Immunol 2013; 191: 1175-1187.
35. Miron VE, Boyd A, Zhao JW, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013; 16: 1211-1218.
36. Grant JL, Ghosn EE, Axtell RC, et al. Reversal of paralysis and reduced inflammation from peripheral administration of beta-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 2012; 4: 145ra05.
37. Gourraud PA, McElroy JP, Caillier SJ, et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol 2011; 69: 65-74.
38. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477-493.
39. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (pt 4): 1089-1104. (Pubitemid 47355604)
40. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135 (pt 10): 2925-2937.
41. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646-657. (Pubitemid 33021923)
42. Lassmann H,. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013 Jun 2. doi:pii: S0022-510X(13)00217-7. 10.1016/j.jns.2013.05.010. [Epub ahead of print].
43. Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006; 65: 855-865. (Pubitemid 44371231)
44. Ouardouz M, Coderre E, Basak A, et al. Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 2009; 65: 151-159.
45. Ouardouz M, Coderre E, Zamponi GW, et al. Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol 2009; 65: 160-166.
46. Mahad D, Ziabreva I, Lassmann H, Turnbull D,. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008; 131 (pt 7): 1722-1735. (Pubitemid 351957459)
47. Lassmann H, van Horssen J,. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011; 585: 3715-3723.
48. Hametner S, Wimmer I, Haider L, et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013 Jul 19. doi: 10.1002/ana.23974. [Epub ahead of print].
49. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011; 69: 481-492.
50. Nave KA,. Myelination and support of axonal integrity by glia. Nature 2010; 468: 244-252.
51. Manrique-Hoyos N, Jurgens T, Gronborg M, et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012; 71: 227-244.
52. Ochoa-Reparaz J, Mielcarz DW, Begum-Haque S, Kasper LH,. Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. Ann Neurol 2011; 69: 240-247.
53. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538-541.
54. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72: 53-64.
55. von Budingen HC, Bar-Or A, Zamvil SS,. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011; 23: 713-720.
56. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008; 14: 688-693. (Pubitemid 351809541)
57. von Budingen HC, Kuo TC, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 2012; 122: 4533-4543.
58. Couturier N, Bucciarelli F, Nurtdinov RN, et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011; 134 (pt 3): 693-703.
59. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; 488: 508-511.
60. Sawcer S, Wason J,. Risk in complex genetics: "all models are wrong but some are useful". Ann Neurol 2012; 72: 502-509.
61. Fernandez O,. Integrating the tools for an individualized prognosis in multiple sclerosis. J Neurol Sci 2013; 331: 10-13.
62. Gresle MM, Butzkueven H, Shaw G,. Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int 2011; 2011: 315406.
63. Schulze -Topphoff U, Casazza S, Varrin-Doyer M, et al. Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med 2013; 210: 1301-1309.
64. Anderson AC, Chandwaskar R, Lee DH, et al. A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. J Immunol 2012; 188: 2084-2092.
65. Anderson JM, Hampton DW, Patani R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008; 131 (pt 7): 1736-1748. (Pubitemid 351957465)
66. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-751. (Pubitemid 43085840)
67. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13: 1228-1233. (Pubitemid 47530642)
68. Charles P, Hernandez MP, Stankoff B, et al. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A 2000; 97: 7585-7590. (Pubitemid 30431507)
69. Back SA, Tuohy TM, Chen H, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005; 11: 966-972. (Pubitemid 41294442)
70. Chong SY, Rosenberg SS, Fancy SP, et al. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci U S A 2012; 109: 1299-1304.
71. Fancy SP, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009; 23: 1571-1585.
72. Wang S, Sdrulla AD, diSibio G, et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998; 21: 63-75. (Pubitemid 28355692)
73. Genoud S, Lappe-Siefke C, Goebbels S, et al. Notch1 control of oligodendrocyte differentiation in the spinal cord. J Cell Biol 2002; 158: 709-718. (Pubitemid 34920109)
74. Watkins TA, Emery B, Mulinyawe S, Barres BA,. Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 2008; 60: 555-569.
75. Zhang Y, Argaw AT, Gurfein BT, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci U S A 2009; 106: 19162-19167.
76. Huang JK, Jarjour AA, Nait Oumesmar B, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 2011; 14: 45-53.
77. Rosenberg SS, Kelland EE, Tokar E, et al. The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation. Proc Natl Acad Sci U S A 2008; 105: 14662-14667.
78. Lee S, Leach MK, Redmond SA, et al. A culture system to study oligodendrocyte myelination processes using engineered nanofibers. Nat Methods 2012; 9: 917-922.
79. Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012; 487: 443-448.
80. Funfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485: 517-521.
81. Fruhbeis C, Frohlich D, Kuo WP, et al. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol 2013; 11: e1001604.